Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news: KZ +6.7% (receives 'going private' offer from group led by Chairman/CEO for $8.56/share), SYY +1.6% (terminated its merger agreement with US Foods; announces $3 billion share repurchase), POT +0.7% (will not make divestments for any possible M&A deal with K&S (KPLUF), according to Reuters), .
Other news: PETX +17.9% (nnounces positive results from its pivotal field effectiveness study of capromorelin for appetite stimulation in dogs), WYY +6.5% (enters strategic alliance with Samsung (SSNLF) SDS America that enables WidePoint Certificate-on-Device digital certificates for use on Samsung Galaxy S devices), SYN +5.2% (initiates a Phase 2 clinical trial of SYN-010 to treat irritable bowel syndrome with constipation), SRPT +1.3% (completes NDA Submission to FDA for Eteplirsen)
Analyst comments: MUX +7% (assumed with a Buy at H.C. Wainwright ), PTX +3.4% (initiated with a Buy at Brean Capital; tgt $17)
In reaction to strong earnings/guidance: N/A.
M&A news: KZ +6.7% (receives 'going private' offer from group led by Chairman/CEO for $8.56/share), SYY +1.6% (terminated its merger agreement with US Foods; announces $3 billion share repurchase), POT +0.7% (will not make divestments for any possible M&A deal with K&S (KPLUF), according to Reuters), .
Other news: PETX +17.9% (nnounces positive results from its pivotal field effectiveness study of capromorelin for appetite stimulation in dogs), WYY +6.5% (enters strategic alliance with Samsung (SSNLF) SDS America that enables WidePoint Certificate-on-Device digital certificates for use on Samsung Galaxy S devices), SYN +5.2% (initiates a Phase 2 clinical trial of SYN-010 to treat irritable bowel syndrome with constipation), SRPT +1.3% (completes NDA Submission to FDA for Eteplirsen)
Analyst comments: MUX +7% (assumed with a Buy at H.C. Wainwright ), PTX +3.4% (initiated with a Buy at Brean Capital; tgt $17)